ANDA 200144, held by Rising Pharmaceuticals. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 200144 (Idarubicin Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Oct 11, 2012, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 11, 2012 | Original application | Approved | None posted |
| Idarubicin Hydrochloride5MG/5ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride10MG/10ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride20MG/20ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Sep 24, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 24, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 11, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters